--- title: "Can Kyowa Kirin (TSE:4151) Sustain Its Stronger Profit Conversion And Evolving Investment Narrative?" type: "News" locale: "en" url: "https://longbridge.com/en/news/295157372.md" description: "Kyowa Kirin reported strong H1 2026 results, with sales rising to ¥263.6 billion and net income doubling to ¥30.6 billion, highlighting improved profit conversion. While this reinforces its investment narrative of steady growth, the market remains cautious due to slower forecasted revenue growth and execution risks regarding its drug pipeline. Despite recent profitability gains, some analyses suggest the stock may still be trading above fair value." datetime: "2026-08-06T23:48:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295157372.md) - [en](https://longbridge.com/en/news/295157372.md) - [zh-HK](https://longbridge.com/zh-HK/news/295157372.md) --- # Can Kyowa Kirin (TSE:4151) Sustain Its Stronger Profit Conversion And Evolving Investment Narrative? - Kyowa Kirin Co., Ltd. reported past half-year results for the period ended June 30, 2026, with sales rising to ¥263,629 million from ¥230,654 million and net income increasing to ¥30,618 million from ¥16,320 million a year earlier, lifting basic earnings per share from continuing operations to ¥58.48 from ¥31.18. - The sharp improvement in profitability relative to last year highlights how Kyowa Kirin converted higher sales into stronger earnings, which can reshape perceptions of its business performance. - With recent results showing stronger profit conversion from higher sales, we will now examine how this may influence Kyowa Kirin’s investment narrative. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality. ## What Is Kyowa Kirin's Investment Narrative? To own Kyowa Kirin, you need to believe in a steady, research‑driven pharmaceuticals business that can convert a modest sales base into consistently improving profits, while funding a pipeline that includes ziftomenib and the rocatinlimab program. The latest half‑year results, with stronger earnings on higher sales, reinforce the near‑term catalyst of better profit conversion, especially after a period where the share price has lagged both the market and the broader pharma sector. That said, the muted share price over the past month suggests the market is still weighing slower forecast revenue and earnings growth against this step‑up in profitability, so the earnings beat may not radically shift sentiment on its own. Execution risk around pipeline progress and the newer, less seasoned board remains central to the story. However, one key execution risk could still upset this improved profit picture. Despite retreating, Kyowa Kirin's shares might still be trading 30% above their fair value. Discover the potential downside here. ## Exploring Other Perspectives TSE:4151 1-Year Stock Price Chart The Simply Wall St Community currently offers 1 fair value view for Kyowa Kirin at ¥2,245, underlining how a single retail perspective can differ from prevailing market pricing. Set against recent profit strength and slower expected growth, this highlights why it helps to weigh multiple viewpoints on how sustainable today’s margin improvement really is. Explore another fair value estimate on Kyowa Kirin - why the stock might be worth as much as ¥2245! ## Decide For Yourself Don't just follow the ticker - dig into the data and build a conviction that's truly your own. - A great starting point for your Kyowa Kirin research is our analysis highlighting 4 key rewards that could impact your investment decision. - Our free Kyowa Kirin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kyowa Kirin's overall financial health at a glance. ## Searching For A Fresh Perspective? Early movers are already taking notice. See the stocks they're targeting before they've flown the coop: - Find 18 companies with promising cash flow potential yet trading below their fair value. - AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. - Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Valuation is complex, but we're here to simplify it. Discover if Kyowa Kirin might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [4151.JP](https://longbridge.com/en/quote/4151.JP.md) ## Related News & Research - [How Cognizant’s AI-Powered Benchling Deployment at Kyowa Kirin (CTSH) Has Changed Its Investment Story](https://longbridge.com/en/news/296072336.md) - [Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategy](https://longbridge.com/en/news/295714112.md) - [BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline | BNXTF Stock News](https://longbridge.com/en/news/296092823.md) - [Do FCE's (TSE:9564) Earnings Warrant Your Attention?](https://longbridge.com/en/news/295720799.md) - [18:16 ETInnorna für den „Prix Galien USA Best Startup Award" 2026 nominiert](https://longbridge.com/en/news/295854094.md)